2024/25 publications

Between 1 April 2024 and 31 March 2025, the following articles were published which relate to studies that have been supported by the NIHR Sheffield Clinical Research Facility (CRF).

A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest (STH22041: PARAMEDIC-3)

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial (STH18234: MARS 2)

Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation (STH21500: BHF PROTECT-TAVI)

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials (STH20723 & STH20735)

Clinical and cost-effectiveness of pessary self-management versus clinic-based care for pelvic organ prolapse in women: the TOPSY RCT with process evaluation (STH20486: TOPSY)

High Prevalence of Platelet Function Disorders in Women Referred for Surgical Management of Refractory Heavy Menstrual Bleeding (STH18932: MENORRHAGIA)

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial (STH20803: STAND)

Now where do we STAND with crizanlizumab? (STH20803: STAND)

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients (STH21731: OCTAVE)

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study (STH22881: FRONTIER4)

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease (STH18220: ISARIC & STH21439: PHOSP-COVID)

1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study (STH18220: ISARIC & STH21439: PHOSP-COVID)

Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study (STH21439: PHOSP-COVID)

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study (STH21113: Raise XT)

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial (STH21422: ADHERE)

Post-hospitalisation COVID-19 cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction (STH21428: PAN-NPC (COVID-CNS))

Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities (STH18766: REPAIR)

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial (STH19164: BASIL-3)